Leap Therapeutics, Inc.
LPTX
$0.2863
-$0.0059-2.02%
| Weiss Ratings | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.34 | |||
| Price History | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.57% | |||
| 30-Day Total Return | -40.72% | |||
| 60-Day Total Return | -90.64% | |||
| 90-Day Total Return | -88.64% | |||
| Year to Date Total Return | -91.11% | |||
| 1-Year Total Return | -88.90% | |||
| 2-Year Total Return | -90.91% | |||
| 3-Year Total Return | -98.36% | |||
| 5-Year Total Return | -98.22% | |||
| 52-Week High % Change | -93.90% | |||
| 52-Week Low % Change | 31.44% | |||
| Price | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.79 | |||
| 52-Week Low Price | $0.22 | |||
| 52-Week Low Price (Date) | Apr 04, 2025 | |||
| 52-Week High Price (Date) | Oct 30, 2024 | |||
| Valuation | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 12.06M | |||
| Enterprise Value | -34.93M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.85 | |||
| Earnings Per Share Growth | -63.78% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.32 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.29 | |||
| Enterprise Value/EBITDA (TTM) | 0.50 | |||
| Enterprise Value/EBIT | 0.50 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 41.25M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 714 0360 | |||
| Address | 47 Thorndike Street Cambridge, MA 02141 | |||
| Website | www.leaptx.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -71.81% | |||
| Return on Equity | -- | |||
| Income Statement | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -70.05M | |||
| EBIT (TTM) | -70.06M | |||
| Net Income (TTM) | -67.79M | |||
| Net Income Avl. to Common (TTM) | -67.79M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -23.79% | |||
| EPS Diluted (TTM) | -1.85 | |||
| EPS Diluted Growth (Q YOY) | 17.80% | |||
| Balance Sheet | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 47.25M | |||
| Cash Per Share (Q) | $1.15 | |||
| Total Current Assets (Q) | 48.04M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 35.05M | |||
| Current Ratio (Q) | 3.413 | |||
| Book Value Per Share (Q) | $0.91 | |||
| Total Assets (Q) | 49.12M | |||
| Total Current Liabilities (Q) | 14.08M | |||
| Total Debt (Q) | 266.00K | |||
| Total Liabilities (Q) | 14.08M | |||
| Total Common Equity (Q) | 35.05M | |||
| Cash Flow | LPTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 37.18M | |||
| Net Change in Cash (TTM) | -23.39M | |||
| Levered Free Cash Flow (TTM) | -36.72M | |||
| Cash from Operations (TTM) | -60.30M | |||
